Get started
Author

Marina Parry

Genetics and Prognostication in Splenic Marginal Zone Lymphoma: Revelations from Deep Sequencing
2015 · Marina Parry, Matthew J.J. Rose-Zerilli, et al. · Clinical Cancer Research · 153
PDF
A Modified Newcastle-Ottawa Scale for Assessment of Study Quality in Genetic Urological Research
2020 · Joseph M. Norris, Benjamin S. Simpson, et al. · European Urology · 119
PDF
Whole Exome Sequencing Identifies Novel Recurrently Mutated Genes in Patients with Splenic Marginal Zone Lymphoma
2013 · Marina Parry, Matthew J. J. Rose-Zerilli, et al. · PLoS ONE · 91
PDF
Genetic Landscape of Prostate Cancer Conspicuity on Multiparametric Magnetic Resonance Imaging: A Systematic Review and Bioinformatic Analysis
2020 · Joseph M. Norris, Benjamin S. Simpson, et al. · European Urology Open Science · 43
PDF
Genomic Evaluation of Multiparametric Magnetic Resonance Imaging-visible and -nonvisible Lesions in Clinically Localised Prostate Cancer
2018 · Marina A. Parry, Shambhavi Srivastava, et al. · European Urology Oncology · 39
PDF
Tumor transcriptome-wide expression classifiers predict treatment sensitivity in advanced prostate cancers
2025 · Emily Grist, Peter Dutey-Magni, et al. · Cell · 36
PDF
Genomic Profiles of De Novo High- and Low-Volume Metastatic Prostate Cancer: Results From a 2-Stage Feasibility and Prevalence Study in the STAMPEDE Trial
2020 · Clare Gilson, Fiona Ingleby, et al. · JCO Precision Oncology · 34
Accumulation of copy number alterations and clinical progression across advanced prostate cancer
2022 · Emily Grist, Stefanie Friedrich, et al. · Genome Medicine · 30
PDF
Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol
2025 · Silke Gillessen, Silke Gillessen, et al. · The Lancet Oncology · 27
PDF
Fine-Mapping CASP8 Risk Variants in Breast Cancer
2012 · Nicola J. Camp, Marina Parry, et al. · Cancer Epidemiology Biomarkers & Prevention · 26
External validation of a digital pathology-based multimodal artificial intelligence-derived prognostic model in patients with advanced prostate cancer starting long-term androgen deprivation therapy: a post-hoc ancillary biomarker study of four phase 3 randomised controlled trials of the STAMPEDE platform protocol
2025 · Charles T A Parker, Larissa Mendes, et al. · The Lancet Digital Health · 25
PDF
Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis
2015 · N. Winkelmann, M. Rose-Zerilli, et al. · Haematologica · 24
PDF
The National Cancer Audit Collaborating Centre (NATCAN): improving the quality of National Health Service cancer care in England and Wales
2025 · Ajay Aggarwal, David Cromwell, et al. · The Lancet Oncology · 15
PDF
Splenic marginal-zone lymphoma: ontogeny and genetics
2014 · Panagiotis Baliakas, Jonathan C. Strefford, et al. · Leukemia & lymphoma/Leukemia and lymphoma · 15
Introducing the Metastatic Breast Cancer Project: a novel patient-partnered initiative to accelerate understanding of MBC
2018 · Marina Parry · ESMO Open · 14
Molecular analysis of single circulating tumour cells following long‐term storage of clinical samples
2017 · Barbara Mesquita, Dominic G. Rothwell, et al. · Molecular Oncology · 14
PDF
Copy number architectures define treatment-mediated selection of lethal prostate cancer clones
2023 · A. M. Mahedi Hasan, Paolo Cremaschi, et al. · Nature Communications · 13
PDF
Clinical testing of transcriptome-wide expression profiles in high-risk localized and metastatic prostate cancer starting androgen deprivation therapy: an ancillary study of the STAMPEDE abiraterone Phase 3 trial
2023 · Gerhardt Attard, Marina Parry, et al. · Research Square · 13
PDF
1596O Decipher mRNA score for prediction of survival benefit from docetaxel at start of androgen deprivation therapy (ADT) for advanced prostate cancer (PC): An ancillary study of the STAMPEDE docetaxel trials
2024 · E. Grist, P. Dutey-Magni, et al. · Annals of Oncology · 12
Discordant Haplotype Sequencing Identifies Functional Variants at the 2q33 Breast Cancer Risk Locus
2016 · Nicola J. Camp, Wei-Yu Lin, et al. · Cancer Research · 12
Genetic landscape of prostate cancer conspicuity on multiparametric MRI: a protocol for a systematic review and bioinformatic analysis
2020 · Joseph M Norris, Benjamin S Simpson, et al. · BMJ Open · 10
PDF
Genetic correlates of prostate cancer visibility (and invisibility) on multiparametric magnetic resonance imaging: it's time to take stock
2019 · Joseph M. Norris, Benjamin S. Simpson, et al. · British Journal of Urology · 10
Geographic, socioeconomic and demographic inequalities in the incidence of metastatic prostate cancer at time of diagnosis in England: a population-based evaluation
2025 · Joanna Dodkins, Adrian Cook, et al. · BMJ Oncology · 9
PDF
CBL-MZ is not a single biological entity: evidence from genomic analysis and prolonged clinical follow-up
2018 · Helen Parker, Neil Robert McIver-Brown, et al. · Blood Advances · 9
PDF
Are evidence-based guidelines translating into clinical practice? A national population-based study of the use of treatment intensification in metastatic hormone-sensitive prostate cancer (mHSPC) in England
2025 · Joanna Dodkins, Adrian Cook, et al. · European Journal of Cancer · 8
PDF
Works count: 102
Citation count: 828
H-index: 14
I10-index: 22
Year
Topic
Type